阿片受体激动剂治疗带回家剂量增加与阿片过量及治疗中断和终止的关联
该回顾性倾向加权队列研究纳入2020年3月21日加拿大安大略省21 297名正在接受阿片受体激动剂治疗(OAT)者,评估2020年3月22日至4月21日带回家剂量变化与随后180天内阿片过量、治疗中断和终止的关联。每日分发美沙酮者中,开始带回家剂量与阿片过量(6.9% vs 9.5%/人年;加权HR 0.73 [95%CI 0.56-0.96])、治疗终止(51.0% vs 63.6%/人年;加权HR 0.80 [95%CI 0.72-0.90])和治疗中断(19.0% vs 23.9%/人年;加权HR 0.80 [95%CI 0.67-0.95])风险降低显著相关。每周分发美沙酮者延长带回家剂量与治疗终止(14.1% vs 19.6%/人年;加权HR 0.72 [95%CI 0.62-0.84])和中断(5.1% vs 7.4%/人年;加权HR 0.69 [95%CI 0.53-0.90])风险降低显著相关,每周分发丁丙诺啡/纳洛酮者延长带回家剂量与治疗中断风险降低显著相关(9.5% vs 12.9%/人年;加权HR 0.74 [95%CI 0.56-0.99])。作者结论认为这些发现可能受残余混杂影响,应谨慎解读。
要点
- 每日分发美沙酮者开始带回家剂量后,阿片过量风险显著低于无变化者(6.9% vs 9.5%/人年;加权HR 0.73 [95%CI 0.56-0.96])。
- 每日分发美沙酮者开始带回家剂量后,治疗终止(加权HR 0.80 [95%CI 0.72-0.90])和治疗中断(加权HR 0.80 [95%CI 0.67-0.95])风险均显著降低。
- 每周分发美沙酮者延长带回家剂量后,治疗终止(加权HR 0.72 [95%CI 0.62-0.84])和中断(加权HR 0.69 [95%CI 0.53-0.90])风险显著降低。
- 每周分发丁丙诺啡/纳洛酮者延长带回家剂量后,治疗中断风险显著降低(9.5% vs 12.9%/人年;加权HR 0.74 [95%CI 0.56-0.99]),其他主要结局无显著差异。
- 每日分发丁丙诺啡/纳洛酮者中,带回家剂量变化与任何结局均无显著差异。
适用人群与场景
- 2020年3月21日在加拿大安大略省正在接受阿片受体激动剂治疗(OAT)的21 297人(美沙酮16 862人,丁丙诺啡/纳洛酮4435人)。
- 按OAT种类和基线带回家剂量频率分为4个队列:每日分发美沙酮、每周5-6次带回家美沙酮、每日分发丁丙诺啡/纳洛酮、每周5-6次带回家丁丙诺啡/纳洛酮。
研究设计与关键结果
- 研究设计:回顾性倾向加权队列研究,纳入2020年3月21日正在接受OAT的21 297人,暴露为2020年3月22日至4月21日期间带回家剂量延长,随访至180天(末次随访日期2020年10月18日)。
- 每日分发美沙酮组(n=5852):开始带回家剂量与阿片过量风险降低显著相关(6.9% vs 9.5%/人年;加权HR 0.73 [95%CI 0.56-0.96]),与治疗终止(51.0% vs 63.6%/人年;加权HR 0.80 [95%CI 0.72-0.90])和治疗中断(19.0% vs 23.9%/人年;加权HR 0.80 [95%CI 0.67-0.95])风险降低显著相关。
- 每日分发丁丙诺啡/纳洛酮组(n=662):暴露组与对照组在任何结局上均无显著差异。
- 每周分发美沙酮组(n=11 010):延长带回家剂量与治疗终止(14.1% vs 19.6%/人年;加权HR 0.72 [95%CI 0.62-0.84])和治疗中断(5.1% vs 7.4%/人年;加权HR 0.69 [95%CI 0.53-0.90])风险降低显著相关;其他主要结局组间无显著差异。
- 每周分发丁丙诺啡/纳洛酮组(n=3773):延长带回家剂量与治疗中断风险降低显著相关(9.5% vs 12.9%/人年;加权HR 0.74 [95%CI 0.56-0.99]);其他主要结局组间无显著差异。
证据类型、等级与局限
- 证据类型:回顾性倾向加权队列研究。
- 局限:原文述这些发现可能受残余混杂影响,应谨慎解读。
对床旁实践的改变
- 作者结论认为,在加拿大安大略省新冠疫情期间,增加OAT带回家剂量与部分患者亚组治疗中断和终止率降低显著相关,6个月随访内阿片相关过量无统计学显著增加;这些发现可能受残余混杂影响,应谨慎解读。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: During the COVID-19 pandemic, modified guidance for opioid agonist therapy (OAT) allowed prescribers to increase the number of take-home doses to promote treatment retention. Whether this was associated with an increased risk of overdose is unclear.
OBJECTIVE: To evaluate whether increased take-home doses of OAT early in the COVID-19 pandemic was associated with treatment retention and opioid-related harm.
DESIGN, SETTING, AND PARTICIPANTS: A retrospective propensity-weighted cohort study of 21 297 people actively receiving OAT on March 21, 2020, in Ontario, Canada. Changes in OAT take-home dose frequency were assessed between March 22, 2020, and April 21, 2020, and individuals were observed for up to 180 days to assess outcomes (last date of follow-up, October 18, 2020).
EXPOSURES: Exposure was defined as extended take-home doses in the first month of the pandemic within each of 4 cohorts based on OAT type and baseline take-home dose frequency (daily dispensed methadone, 5-6 take-home doses of methadone, daily dispensed buprenorphine/naloxone, and 5-6 take-home doses of buprenorphine/naloxone).
MAIN OUTCOMES AND MEASURES: Primary outcomes were opioid overdose, interruption in OAT, and OAT discontinuation.
RESULTS: Among 16 862 methadone and 4435 buprenorphine/naloxone recipients, the median age ranged between 38 and 42 years, and 29.1% to 38.2% were women. Among individuals receiving daily dispensed methadone (n = 5852), initiation of take-home doses was significantly associated with lower risks of opioid overdose (6.9% vs 9.5%/person-year; weighted hazard ratio [HR], 0.73 [95% CI, 0.56-0.96]), treatment discontinuation (51.0% vs 63.6%/person-year; weighted HR, 0.80 [95% CI, 0.72-0.90]), and treatment interruption (19.0% vs 23.9%/person-year; weighted HR, 0.80 [95% CI, 0.67-0.95]) compared with no change in take-home doses. Among individuals receiving daily dispensed buprenorphine/naloxone (n = 662), there was no significant difference in any outcomes between exposure groups. Among individuals receiving weekly dispensed OAT (n = 11 010 for methadone; n = 3773 for buprenorphine/naloxone), extended take-home methadone doses were significantly associated with lower risks of OAT discontinuation (14.1% vs 19.6%/person-year; weighted HR, 0.72 [95% CI, 0.62-0.84]) and interruption in therapy (5.1% vs 7.4%/person-year; weighted HR, 0.69 [95% CI, 0.53-0.90]), and extended take-home doses of buprenorphine/naloxone were significantly associated with lower risk of interruption in therapy (9.5% vs 12.9%/person-year; weighted HR, 0.74 [95% CI, 0.56-0.99]) compared with no change in take-home doses. Other primary outcomes were not significantly different between groups.
CONCLUSIONS AND RELEVANCE: In Ontario, Canada, during the COVID-19 pandemic, dispensing of increased take-home doses of opioid agonist therapy was significantly associated with lower rates of treatment interruption and discontinuation among some subsets of patients receiving opioid agonist therapy, and there were no statistically significant increases in opioid-related overdoses over 6 months of follow-up. These findings may be susceptible to residual confounding and should be interpreted cautiously.
参考来源
- Gomes T, Campbell TJ, Kitchen SA, et al. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation. JAMA. 2022. PMID: 35230394. doi:10.1001/jama.2022.1271
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。